Intracranial stereotaxic cannulation for development of orthotopic glioblastoma allograft in Sprague-Dawley rats and histoimmunopathological characterization of the brain tumor.
Glioblastoma is the most common brain tumor that causes significant mortality annually. Limitations of the current therapeutic regimens warrant development of new techniques and treatment strategies in orthotopic animal model for better management of this devastating brain cancer. There are only a few experimental orthotopic models of glioblastoma for pre-clinical testing. In the present investigation, we successfully implanted rat C6 cells via intracranial stereotaxic cannulation in adult Sprague-Dawley rats for development and histoimmunopathological characterization of an advanced orthotopic glioblastoma allograft model, which could be useful for investigating the course of glioblastoma development as well as for testing efficacy of new therapeutic agents. The orthotopic glioblastoma allograft was generated by intracerebral injection of rat C6 cells through a guide-cannula system and after 21 post-inoculation days the brain tumor was characterized by histoimmunopathological experiments. Histological staining and immunofluorescent labelings for TERT, VEGF, Bcl-2, survivin, XIAP, and GFAP revealed the distinct characteristics of glioblastoma in C6 allograft, which could be useful as a target for treatment with emerging new therapeutic agents. Our investigation indicated the successful development of intracranial cannulated orthotopic glioblastoma allograft in adult Sprague-Dawley rats, making it as a useful animal model of glioblastoma for pre-clinical evaluation of various therapeutic strategies for the management of glioblastoma.
Karmakar
Surajit
S
Department of Neurosciences, Medical University of South Carolina, Charleston, SC 29425, USA.
Olive
M Foster
MF
Banik
Naren L
NL
Ray
Swapan K
SK
D000818:Animals; D014408:Biomarkers, Tumor; D001932:Brain Neoplasms / Q000473:pathology*; D002404:Catheterization / Q000379:methods; D017690:Cell Transplantation / Q000295:instrumentation / Q000379:methods; D004396:Coloring Agents; D005455:Fluorescent Antibody Technique; D005909:Glioblastoma / Q000473:pathology*; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D008297:Male; D009368:Neoplasm Transplantation / Q000295:instrumentation / Q000379:methods*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013238:Stereotaxic Techniques
D014408:Biomarkers, Tumor; D004396:Coloring Agents
Apoptosis. 2007 Apr;12 (4):671-84
17219050
J Clin Neurosci. 2002 Nov;9(6):668-71
12604281
Arch Pathol Lab Med. 2003 Jul;127(7):826-33
12823036
Oncogene. 1998 Dec 24;17 (25):3247-59
9916987
Neurosurgery. 2000 Oct;47(4):993-9; discussion 999-1000
11014444
Neurosurgery. 1998 May;42(5):1083-99; discussion 1099-100
9588554
Neurol Res. 2006 Jul;28(5):532-7
16808885
Brain Res. 2004 May 1;1006(2):150-6
15051518
Curr Cancer Drug Targets. 2006 Mar;6(2):147-80
16529544
Neuroscience. 2006 Sep 1;141(3):1265-80
16765523
Curr Opin Oncol. 1999 May;11(3):157-61
10328588
Oncogene. 2004 Sep 30;23(45):7494-506
15326475
Am J Clin Oncol. 2002 Feb;25(1):60-4
11823699
Cancer Res. 2001 Dec 1;61(23):8569-77
11731444
Childs Nerv Syst. 2006 Dec;22(12):1519-25
17021732
Neurosci Lett. 2006 Oct 16;407(1):53-8
16949208
J Neurochem. 2007 Jul;102(2):522-38
17596214
J Neurooncol. 2005 Sep;74(3):225-32
16187019
Cancer Lett. 1999 Jul 19;142(1):11-6
10424775
J Neurovirol. 1999 Dec;5(6):538-55
10602396
Neurosurgery. 2000 Oct;47(4):921-9; discussion 929-30
11014432
J Neurochem. 2005 Jan;92(1):1-9
15606891
Cancer. 2002 Aug 1;95(3):641-55
12209758
Cancer. 2005 Jun 15;103(12):2606-15
15880378
J Cereb Blood Flow Metab. 1997 Jul;17(7):713-31
9270488
Lancet. 2002 Mar 23;359(9311):1011-8
11937180
Br J Cancer. 2005 Feb 14;92(3):532-8
15685240
BMC Cancer. 2006 Sep 23;6:226
16995949
J Neurooncol. 2001 May;52(3):205-15
11519850
Expert Opin Investig Drugs. 2003 Dec;12 (12 ):1899-924
14640936
Neurosci Lett. 2007 Mar 30;415(3):242-7
17335970
Cancer Res. 2004 Sep 15;64(18):6381-4
15374943